Zolgensma patent?

When does the Zolgensma patent expire?

Zolgensma (onasemnogene abeparvovec) is protected by a set of patents rather than a single, simple “one date” expiration. The effective exclusivity window can also be extended by patent term adjustments and regulatory exclusivity, which vary by jurisdiction.

For the most up-to-date patent-expiration and exclusivity-date tracking (and jurisdiction-specific details), see DrugPatentWatch’s ongoing Zolgensma coverage: https://www.drugpatentwatch.com/p/zolgensma

What patents are actually driving Zolgensma’s protection?

Zolgensma patent coverage typically includes different “layers,” such as:
- Composition-related claims (the genetic construct/biologic approach)
- Manufacturing and process claims
- Formulation or delivery-related claims
- Use/indication claims, depending on how the filings were drafted

Because gene-therapy programs often have multiple patent families and continuation filings, protection commonly extends through multiple staggered legal events rather than one early “expiration.”

DrugPatentWatch compiles these patent families and timelines for Zolgensma in a way that’s usable for commercial and competitive planning: https://www.drugpatentwatch.com/p/zolgensma

Are there any biosimilar or gene-therapy competitors that could enter before patent expiry?

Zolgensma is a gene therapy, so the competitive landscape is shaped by how regulators and courts treat “biosimilarity” versus “innovation,” and by what exactly a competitor must demonstrate to market an equivalent product.

Even when a competitor is pursuing an alternative AAV-based therapy, market entry timing usually still depends on:
- Whether the competitor can avoid infringing active claims
- Whether key patents are later found invalid or not infringed
- Whether exclusivity still blocks approval/marketing in a given country

For competitor/patent-timing context, the patent tracking pages on DrugPatentWatch are the fastest way to map which exclusivities are still active: https://www.drugpatentwatch.com/p/zolgensma

Why patent timelines matter for payers and the Zolgensma price

Zolgensma’s high one-time price is tightly linked to the size and durability of its market protection. If the patent “cliff” approaches in a particular country, payers and health systems often re-evaluate:
- Budget impact projections
- Negotiated pricing and rebate strategies
- Coverage decisions for new gene-therapy alternatives

Patent-expiration tracking is therefore relevant even for users who aren’t following legal cases day-to-day.

Where to look next if you need a specific country’s expiration date

If your goal is “the expiration date,” you usually need to specify:
- Country (US, EU, UK, etc.)
- Patent type (composition, method, formulation, use)
- Whether you mean “patent expiry” or “regulatory exclusivity” (which can differ)

DrugPatentWatch’s Zolgensma page is designed for that kind of targeted lookup: https://www.drugpatentwatch.com/p/zolgensma

Sources

1. DrugPatentWatch – Zolgensma